These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 11383596)
21. TNF-alpha antagonists for the treatment of Crohn's disease. Kam LY; Targan SR Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506 [TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ; J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336 [TBL] [Abstract][Full Text] [Related]
23. Infliximab-induced thrombocytopenia in an elderly patient with ileocolonic Crohn's disease. Mocciaro F; Russo G; Di Mitri R; Marino A Inflamm Bowel Dis; 2013; 19(4):E52-3. PubMed ID: 22535599 [No Abstract] [Full Text] [Related]
24. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441 [TBL] [Abstract][Full Text] [Related]
25. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication]. Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805 [TBL] [Abstract][Full Text] [Related]
26. The effect of controlling inflammatory activity in the colon on the response to infliximab of autoimmune haemolytic anaemia associated with ulcerative colitis. Leo-Carnerero E; Araujo-Míguez A; Trigo-Salado C; De-la-Cruz-Ramírez MD; Herrera-Justiniano JM; Márquez-Galán JL Rev Esp Enferm Dig; 2014 Apr; 106(4):295-6. PubMed ID: 25075665 [No Abstract] [Full Text] [Related]
27. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Seiderer J; Göke B; Ochsenkühn T Digestion; 2004; 70(1):3-9. PubMed ID: 15297773 [TBL] [Abstract][Full Text] [Related]
28. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Panaccione R; Fedorak RN; Aumais G; Bernard EJ; Bernstein CN; Bitton A; Croitoru K; Dieleman LA; Enns R; Feagan BG; Franchimont D; Greenberg GR; Griffiths AM; Marshall JK; Pare P; Patel S; Penner R; Render C; Seidman E; Steinhart AH Can J Gastroenterol; 2008 Mar; 22(3):261-72. PubMed ID: 18354755 [TBL] [Abstract][Full Text] [Related]
29. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Rutgeerts P; Van Assche G; Vermeire S Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465 [TBL] [Abstract][Full Text] [Related]
30. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for). Shanahan F Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074 [No Abstract] [Full Text] [Related]
31. Maintenance drugs for inflammatory bowel disease. Drug Ther Bull; 2001 Dec; 39(12):91-5. PubMed ID: 11799594 [TBL] [Abstract][Full Text] [Related]
32. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center. Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991 [TBL] [Abstract][Full Text] [Related]
33. Safety of infliximab in patients suffering from inflammatory bowel disease. Felley C; Michetti P Digestion; 2004; 70(1):1-2. PubMed ID: 15297772 [No Abstract] [Full Text] [Related]
34. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to? Gearry RB; Irving PM J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189 [No Abstract] [Full Text] [Related]
35. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314 [TBL] [Abstract][Full Text] [Related]
36. How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes. St-Pierre J; Chadee K Dig Dis Sci; 2014 Apr; 59(4):712-5. PubMed ID: 24504593 [No Abstract] [Full Text] [Related]
37. Infliximab therapy for ulcerative colitis: many unanswered questions. Present DH Am J Gastroenterol; 2001 Aug; 96(8):2294-6. PubMed ID: 11513164 [No Abstract] [Full Text] [Related]
38. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review. Da W; Zhu J; Wang L; Lu Y Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447 [TBL] [Abstract][Full Text] [Related]
39. Infliximab in inflammatory bowel disease: attention to adverse events. Uyanikoglu A; Ermis F; Akyuz F; Pinarbasi B; Baran B; Aydogan T; Demir K; Besisik F; Kaymakoglu S Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2337-42. PubMed ID: 25219835 [TBL] [Abstract][Full Text] [Related]
40. Severe neutropenia following infliximab treatment in a child with ulcerative colitis. Sherlock ME; Bandsma R; Ota K; Kirby-Allen M; Griffiths AM Inflamm Bowel Dis; 2011 Feb; 17(2):E17-8. PubMed ID: 20824816 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]